Stryker expects 8.3%-9.3% organic sales growth and $14.95-$15.10 adjusted EPS in 2026 as it resumes share repurchases (NYSE:SYK)

Stryker (SYK) delivered strong forward guidance for 2026, projecting 8.3%-9.3% organic sales growth and adjusted EPS of $14.95-$15.10, representing mid-to-high single-digit earnings expansion. The resumption of share repurchases signals management confidence in cash generation and capital allocation discipline, a positive signal for shareholder returns in a recovery phase.

Q2 2026 results showing 9% organic growth and $3.69 EPS demonstrate operational momentum across the medical device portfolio. The company's ability to navigate cyber recovery initiatives and supply chain headwinds while maintaining growth trajectory underscores resilient demand in healthcare capital equipment and orthopedic/surgical solutions, core exposure areas for SYK in an aging demographic environment.

The buyback resumption combined with organic growth guidance suggests management views current valuations as attractive relative to forward earnings power. This capital allocation stance, coupled with guidance narrowing and mid-point growth visibility, typically attracts institutional capital rotation into cyclical healthcare equities amid broader economic normalization.

Sector implication: Medical device and healthcare services sectors remain structurally supported by demographic tailwinds, insurance coverage expansion, and elective procedure recovery. SYK's guidance reaffirms investor confidence in diversified medtech exposure and positions the subsector favorably relative to defensive rotations, though supply chain monitoring remains material to execution risk.